Loading organizations...
Acadia Pharmaceuticals is a San Diego, California biopharmaceutical company that discovers, develops, and commercializes proprietary small molecule therapies for central nervous system disorders and rare psychiatric conditions. The publicly traded enterprise operates with a workforce of over 600 employees and reported approximately $726 million in annual net product sales for fiscal year 2023. The firm generates its primary revenue through the commercial sale of its approved prescription medications, including flagship products NUPLAZID for Parkinson's disease psychosis and DAYBUE for Rett syndrome. To support its clinical pipeline and commercialization efforts, the organization has engaged in strategic licensing agreements and secured financing from corporate partners and institutional investors including Allergan and BankInvest. Originally founded under the name Receptor Technologies in 1993 by Mark Brann and Edward Holmes, the company is led by Chief Executive Officer Catherine Owen Adams.
Acadia Pharmaceuticals Inc. has raised $25.0M across 1 funding round.
Acadia Pharmaceuticals Inc. has raised $25.0M in total across 1 funding round.
Acadia Pharmaceuticals Inc. has raised $25.0M in total across 1 funding round.
Acadia Pharmaceuticals Inc.'s investors include OrbiMed.
Acadia Pharmaceuticals Inc. is a biopharmaceutical company, not a technology company, focused on developing and commercializing therapies for central nervous system (CNS) disorders and rare neurological diseases.[1][2][3] It serves patients with unmet needs in areas like Parkinson's disease psychosis, Rett syndrome, and other underserved conditions through flagship products such as Nuplazid (pimavanserin) for hallucinations and delusions in Parkinson's and DAYBUE (trofinetide) as the first approved therapy for Rett syndrome.[1][2][4] The company addresses critical gaps in treatment options, with a pipeline including pimavanserin for Alzheimer's agitation, schizophrenia, and depression, plus collaborations for RNA-based therapies in rare genetic neurodevelopmental diseases.[1][2][4]
Acadia's growth momentum stems from a proven commercial portfolio, recent regulatory approvals like DAYBUE in the US and Canada, and strategic partnerships, such as with Stoke Therapeutics and Saniona AB, positioning it for expansion in neurology and rare diseases.[2][4]
Acadia Pharmaceuticals began in 1993 as Receptor Technologies in Winooski, Vermont, initially focusing on genetic screens for receptors to accelerate early-stage drug discovery.[3][4] In 1997, it rebranded as Acadia Pharmaceuticals—inspired by Acadia National Park—and relocated headquarters to San Diego, California, while establishing a medicinal chemistry center in Copenhagen, Denmark, to attract biotech partnerships; early funding came from Danish investors like BankInvest.[3][4]
The company went public in 2004 via a NASDAQ IPO (ticker: ACAD), raising $35 million amid development of five drugs, followed by a $102 million secondary offering in 2007.[3][4] Pivotal moments include FDA approval of Nuplazid in 2016—the first for Parkinson's disease psychosis—and acquisitions like CerSci Therapeutics in 2020, plus licensing deals for trofinetide, culminating in DAYBUE's 2023 approval.[1][3][4]
Acadia rides the wave of precision neurology and rare disease therapeutics, capitalizing on advances in CNS-targeted small molecules and genetic therapies amid rising demand for treatments in aging populations and orphan diseases.[1][2][5] Timing aligns with regulatory incentives for rare diseases—like FDA approvals for Rett syndrome—and growing biotech investment in neurodevelopmental disorders, where market forces favor first-movers in underserved segments.[4]
It influences the ecosystem through collaborations that accelerate RNA-based and novel CNS innovations, expanding access via approvals in the US, Canada, and MAA filings in Europe, while contributing to global standards in patient-inspired biopharma.[2][4]
Acadia is set to deepen its leadership in CNS and rare diseases, with pipeline readouts like pimavanserin expansions, NNZ-2591 for Fragile X, and new Phase 2 candidates driving revenue growth beyond its established portfolio.[1][4] Trends like AI-aided drug discovery, gene therapy integration, and orphan drug reimbursements will shape its path, potentially amplifying influence through more global approvals and acquisitions.
This positions Acadia to deliver more "meaningful moments" for patients, evolving from niche innovator to broader neurological powerhouse—correcting the tech company misconception by highlighting its biopharma impact.[2]
Acadia Pharmaceuticals Inc. has raised $25.0M across 1 funding round. Most recently, it raised $25.0M Series F in March 2003.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Mar 1, 2003 | $25M Series F | — | OrbiMed | Announced |
